To study the utility of COX2 as immunohistochemical prognostic marker in comparison to various histopathological parameters and TNM staging in colorectal carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Immunohistochemical analysis in determining cox2 expression used as a prognostic marker in colorectal carcinoma in correlation with TNM staging.
研究概览
简要总结
ABSTRACT
Introduction: The most prevalent neoplasm of the gastrointestinal system is colorectal carcinoma. After lung and breast carcinoma, malignant colorectal cancer appears to be characterized by inflammation. Among the numerous recognized indicators of inflammation, Cyclooxygenase-2 (COX-2) has been identified as playing a key role in the early phases of carcinogenesis. The link between higher expression of COX-2 and the early stages of carcinogenesis and cancer development implies that COX-2 might be a target for precancerous colorectal lesion imaging.
Aim: To assess the expression of COX-2 in colorectal carcinoma and the association with histopathological prognostic markers and Tumour Node Metastasis (TNM) staging.
Materials and Methods: The current study is an observational, cross-sectional, retrospective, and prospective study that will take place in the Histopathology and Immunohistochemistry unit of the Department of Pathology, Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra, India, between the years of 2021 and 2024. The study included approximately 60-65 resected specimens from confirmed and planned Colectomy, Hemicolectomy, and Proctocolectomy specimens received in the Department of General Pathology, JNMC. Observations and results will be collected from the immunohistochemistry study by using COX-2 as a prognostic marker in colorectal carcinoma and correlating it with the TNM staging. Statistical analysis will be made by chi-square test and regression analysis.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 45.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •1.All cases diagnosed as colorectal carcinoma on histopathology.
- •2.All colectomy/Hemicolectomy/ Proctocolectomy resection specimens.
- •3.Primary cases of colorectal carcinoma without any history of previous treatment.
- •4.All patients presenting with colorectal carcinoma arising Denovo.
排除标准
- •1.All inflammatory lesions, and other malignancies of the gastrointestinal tract.
- •2.All biopsy specimens.
- •3.All treated cases of colorectal carcinoma and cases with recurrence.
结局指标
主要结局
Immunohistochemical analysis in determining cox2 expression used as a prognostic marker in colorectal carcinoma in correlation with TNM staging.
时间窗: 3 YEARS
次要结局
- It can be used to identify patients with poor clinical outcomes and those who will benefit from early diagnosis.(3 YEARS)